for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arrowhead Pharmaceuticals Inc

ARWR.OQ

Latest Trade

82.07USD

Change

2.05(+2.56%)

Volume

412,087

Today's Range

79.50

 - 

82.24

52 Week Range

19.55

 - 

86.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
80.02
Open
79.81
Volume
412,087
3M AVG Volume
21.04
Today's High
82.24
Today's Low
79.50
52 Week High
86.59
52 Week Low
19.55
Shares Out (MIL)
102.76
Market Cap (MIL)
8,433.25
Forward P/E
-348.34
Dividend (Yield %)
--

Next Event

Q1 2021 Arrowhead Pharmaceuticals Inc Earnings Release

Latest Developments

More

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers Of Alpha-1 Liver Disease

Arrowhead ARO-AAT Phase 2 Interim Results Show Improvements In Key Parameters After 6 Months Of Treatment

Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.13

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry

Biotechnology & Drugs

Contact Info

177 E Colorado Blvd, Suite 700

PASADENA, CA

91105

United States

+1.626.6964702

http://arrowheadpharma.com/

Executive Leadership

Douglass Bruce Given

Chairman of the Board

Christopher Richard Anzalone

President, Chief Executive Officer, Director

Kenneth Allen Myszkowski

Chief Financial Officer

Curt W. Bradshaw

Chief Scientific Officer

Patrick C. O'Brien

General Counsel

Key Stats

2.08 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.2K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2018

-0.650

2019

0.690

2020

-0.840

2021(E)

-0.236
Price To Earnings (TTM)
--
Price To Sales (TTM)
95.84
Price To Book (MRQ)
18.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-23.00
Return on Equity (TTM)
-19.39

Latest News

Latest News

BRIEF-Arrowhead Pharma Reports Quarterly Loss Per Share Of $0.20

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2020 SECOND QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Announces Retirement Of COO Bruce Given

* ARROWHEAD PHARMACEUTICALS ANNOUNCES RETIREMENT OF COO BRUCE GIVEN Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2A Study Of Aro-Enac For Treatment Of Cystic Fibrosis

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2A STUDY OF ARO-ENAC FOR TREATMENT OF CYSTIC FIBROSIS

BRIEF-Arrowhead Pharmaceuticals Announces Precautionary Measures To Mitigate Effects Of Coronavirus Spread

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRECAUTIONARY MEASURES TO MITIGATE EFFECTS OF NOVEL CORONAVIRUS (COVID-19) SPREAD

BRIEF-Arrowhead Pharmaceuticals Initiates Phase 1/2 Study Of ARO-HSD In Normal Healthy Volunteers And Patients With Nash Or Suspected Nash

* ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-HSD IN NORMAL HEALTHY VOLUNTEERS AND PATIENTS WITH NASH OR SUSPECTED NASH Source text for Eikon: Further company coverage:

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc <ARWR.O> said on Thursday Johnson & Johnson <JNJ.N> would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up